XM does not provide services to residents of the United States of America.
W
W

Wacker

Technical Summary

IndicatorValueTrend
IndicatorValueTrend
IndicatorValueTrend
IndicatorS3S2S1PR1R2R3

News

Wacker Chemie's stock rises, analysts point to U.S new duties on solar imports from Southeast Asia

BUZZ-Wacker Chemie's stock rises, analysts point to U.S new duties on solar imports from Southeast Asia ** Wacker Chemie's WCHG.DE stock rises 3.4%, as analysts point to US Commerce Department's anti subsidy countervailing duties on solar cell and panel imports from four southeast Asian countries as a reason for the rise ** "I think the share price rise is due to the announcement of anti subsidy countervailing duties on solar cell and panel imports from four southeast Asian countries by the US C
W

Europe's chemicals rise boosted by Chinese stimulus

BUZZ-Europe's chemicals rise boosted by Chinese stimulus ** European benchmark chemicals index .SX4P is up 2.2%, with German firms leading gains boosted by Chinese stimulus measures announced earlier this week ** BASF BASFn.DE , K+S SDFGn.DE and Wacker Chemie WCHG.DE all rise 5-7% ** Sebastian Bray, analyst at Berenberg, says BASF's shares are also
B
K
W

Burberry, Hermes, Spectris

EUROPE RESEARCH ROUNDUP-Burberry, Hermes, Spectris Sept 20 (Reuters) - Securities analysts revised their ratings and price targets on several European companies including Burberry, Hermes and Spectris on Friday. HIGHLIGHTS * ASML Holding NV ASML.AS : Morgan Stanley cuts to equal-weight from overweight * Burberry BRBY.L : Jefferies cuts to underperform from hold * Hermes HRMS.PA : Jefferies cuts target price to EUR 2,200 from EUR 2,470 * Intercontinental Hotels IHG.L : HSBC cuts target price to 7
A
A
A
B
B
C
C
D
E
E
F
F
G
H
J
K
L
O
R
S
S
W
A
S

Wacker Chemie Confirms Strategy And Long-Term Growth Targets

BRIEF-Wacker Chemie Confirms Strategy And Long-Term Growth Targets Sept 19 (Reuters) - WACKER CHEMIE AG WCHG.DE : WACKER CHEMIE AG - CONFIRMS STRATEGY AND LONG-TERM GROWTH TARGETS WACKER CHEMIE AG - SALES TO REACH 10 BILLION BY 2030; EBITDA MARGIN OF OVER 20 PERCENT TARGETED Source text for Eikon: ID:nPex1H6gTa Further company coverage: WCHG.DE (Gd
W

Wacker Chemie Says Minervax And Wacker Biotech To Collaborate On Prophylactic Vaccine

BRIEF-Wacker Chemie Says Minervax And Wacker Biotech To Collaborate On Prophylactic Vaccine Sept 17 (Reuters) - WACKER CHEMIE AG WCHG.DE : MINERVAX AND WACKER BIOTECH ANNOUNCE MANUFACTURING COLLABORATION FOR PROPHYLACTIC VACCINE TARGETING GROUP B STREPTOCOCCUS MINERVAX SCALING UP SUPPLY OF NOVEL GBS VACCINE, AHEAD OF PHASE III STUDIES WACKER BIOTEC
W

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.